Regenxbio Inc (RGNX) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress and Robust ...
RegenXBio (RGNX) Receives a Buy From Barclays
REGENXBIO Inc. (RGNX) Q1 2024 Earnings Call Transcript
REGENXBIO Inc. (RGNX) Q1 2024 Earnings Call Transcript
Regenxbio Q1 2024 GAAP EPS $(1.38) Misses $(1.23) Estimate, Sales $15.622M Miss $23.525M Estimate
Regenxbio (NASDAQ:RGNX) reported quarterly losses of $(1.38) per share which missed the analyst consensus estimate of $(1.23) by 12.2 percent. This is a 9.8 percent increase over losses of $(1.53) per
Express News | Regenxbio: Sees Balance in Cash, Cash Equivalents and Marketable Securities of $380.5 Mln as of March 31, 2024 to Fund Its Operations Into 2026
Express News | Regenxbio Inc: Qtrly Shr Loss $1.38
Express News | Regenxbio Inc: Qtrly Revenues Were $15.6 Mln Vs $19.1 Mln
Express News | Regenxbio Inc: Cash, Cash Equivalents and Marketable Securities Were $380.5 Mln as of March 31, 2024
Regenxbio: Q1 Earnings Snapshot
Regenxbio | 10-Q: Quarterly report
Earnings Flash (RGNX) REGENXBIO Posts Q1 Revenue $15.6M
04:14 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (RGNX) REGENXBIO Posts Q1 Revenue $15.6M
Press Release: REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights PR Newswire ROCKVILLE, Md., May 8, 2024 -- Company remains on track for its first BLA filing in 2024 and
Express News | Regenxbio Q1 Net Income USD -63.33 Million
Express News | Regenxbio Q1 License & Royalty Revenue USD 15.622 Million
Express News | Regenxbio Q1 Operating Expenses USD 79.485 Million
Express News | Regenxbio Reports First Quarter 2024 Financial Results and Recent Operational Highlights
REGENXBIO 1Q Loss/Shr $1.38 >RGNX
REGENXBIO 1Q Loss/Shr $1.38 >RGNX
REGENXBIO 1Q Loss $63.3M >RGNX
REGENXBIO 1Q Loss $63.3M >RGNX
REGENXBIO 1Q Rev $15.6M >RGNX
REGENXBIO 1Q Rev $15.6M >RGNX
REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., May 1, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. ET to discuss its financial resul
No Data